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In a randomized Phase II trial conducted in patients
with metastatic melanoma, superior overall survival
(p=0.007) was observed for 18 patients treated with vac-
cines that consisted of autologous dendritic cells loaded
with antigens from irradiated autologous melanoma
stem cells, (DC-TC, aka eltrapuldencel-T, NBS20 and
CBLS20) compared to 24 patients treated with vaccines
consisting of autologous irradiated melanoma stem cells
(TC) [ClinicalTrials.gov NCT00436930].[1] Both vaccines
were admixed with GM-CSF as an adjuvant. Tumor cell
lines that served as the source of patient-specific tumor-
associated antigens were derived from metastases
resected from patients with stage IV or recurrent stage
III melanoma. The treatment schedule consisted of
weekly subcutaneous injections for 3 weeks, and then
monthly for 5 months. The current analysis was underta-
ken to determine the treatment effects of DC-TC vs TC
in each of the subsets defined by the pre-randomization
stratifications that were based on whether patients had
measurable or non-measurable disease as defined by
RECIST, and whether their most advanced stage of dis-
ease at the time of randomization had been stage IV or
recurrent stage III disease. At the time of this analysis 5
DC-TC and 3 TC patients had been followed for 5 years;
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Table 1
Stratification Treatment # of patients Median survival in months 3-year overall survival
Measurable DC-TC 8 17.6 33%
Measurable TC 9 6.5 11%
Non-Measurable DC-TC 10 Not Reached 56%
Non-Measurable TC 15 31.3 33%
Recurrent Stage III DC-TC 3 Not Reached 67%
Recurrent Stage III TC 6 30.3 17%
Stage IV DC-TC 15 40.4 60%
Stage IV TC 18 16.9 28%
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5 patients (3 TC and 2 DC-TC) were alive but followed
less than 5 years (minimum 3.5 years); 29 were deceased.
No patients were lost to follow up. The survival results are
summarized in Table 1. Although the numbers are small,
DC-TC immunotherapy was associated with superior sur-
vival in each of the four different subsets defined by the
stratification variables. Eltrapuldencel-T has moved for-
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